Karyopharm Therapeutics | KPTI - Należności Handlowe





Należności Handlowe Zmiana Data
AbbVie USD 12.59B 180M 2025-12
Abbott USD 10.57B 171M 2025-12
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
GlaxoSmithKline GBP 7.94B 178M 2026-03
Incyte USD 1.05B 27.09M 2026-03
J&J USD 21.33B 3.72B 2025-12
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
MacroGenics USD 13.37M 55.86M 2025-12
Merck USD 11.78B 345M 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Novartis USD 9.6B 2.69B 2026-03
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 15.84B 2.27B 2025-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Takeda JPY 757.92B 55.68B 2025-12
Tectonic Therapeutic USD 0 270K 2023-12
TG Therapeutics USD 265.38M 33.86M 2025-09
Ultragenyx Pharmaceutical USD 158M 45.46M 2025-12
Xencor USD 29.3M 7.49M 2025-12